Form D · Biotechnology
Xcell Biosciences, Inc.
San Francisco, CA · CIK 0001697666
Offering snapshot reported Dec 17, 2024 · SEC filing
- Reported sold
- $1.4M Offering amount: $3.5M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Dec 6, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 17, 2024 | Initial | $1,400,000 | No comparison | 5 | SEC filing |
| Sep 13, 2021 | Initial | $15,488,682 | No comparison | Not reported | SEC filing |
| Feb 23, 2017 | Initial | $11,518,571 | No comparison | 33 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-532362
Source: Form D, filed Dec 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Saeid Akhtari | Director |
| Brian S. Feth | Director, Executive |
| James Lim | Executive |
| Kaz Ohno | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
455 Mission Bay Blvd S, Suite 124
San Francisco, CA, 94158
San Francisco, CA, 94158